Clinical Trial Update: Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

Completion of a Phase 1/2 trial evaluating lumiliximab in combination with the FCR regimen for relapsed chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Lumiliximab (Lumiliximab)
• Rituximab (rituximab)

Snippet

Sponsor: Biogen | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED